ESMO guidelines on renal cell carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis

If someone had told us at the beginning of the century that we would have up to 15 different drugs approved for the systemic treatment of patients with metastatic renal cell cancer (mRCC) in 2022, we would not have believed them. 1 https://www.cancer.gov/about-cancer/treatment/drugs/kidneyDate accessed: September 26, 2021 Google Scholar The understanding of the molecular bases of angiogenesis and then the use of vascular endothelial growth...